Excalipoint Launches with $68.7 Million to Advance T-Cell Engager Platforms

Shanghai-based Excalipoint Therapeutics has been launched alongside an oversubscribed $68.7 million in seed financing, the company announced on March 18, 2026. The financing is intended to advance proprietary T-cell engager (TCE) platforms and a pipeline of next-generation immunotherapies targeting oncology and autoimmune diseases.¹

The financing is considered one of the largest seed rounds for a Chinese biotechnology company and includes $41 million raised at inception in August 2025 as well as a $27.7 million extension round supported by global investors, including Eisai’s venture arm, Eisai Innovation, and Lilly Asia Ventures.¹ The capital will support development of multiple technology platforms and six pipeline programs designed to address key limitations of existing TCE therapies.

“Our successful launch and backing from top-tier investors highlight Excalipoint’s strong growth potential,” said Jielun Zhu, co-founder, chief financial officer and chief business officer, Excalipoint Therapeutics, in a company press release.¹ “In just six months, we added two technology platforms and expanded our pipeline to six differentiated programs … we are combining disciplined capital deployment, focused execution, and cross-border partnerships to efficiently translate our science into clinical progress and long-term value.”

How are next-generation TCEs addressing solid tumor challenges?

TCEs have shown promise in hematologic malignancies but face challenges in solid tumors, including limited tumor penetration, immunosuppressive microenvironments, and off-target toxicity.² Excalipoint’s strategy focuses on overcoming these barriers through multi-specific antibody engineering and platform-based design.

The company is developing three proprietary platforms: TOPAbody, T-Cell Immune Shield, and TCE Probody. These platforms are designed to improve the efficacy, safety, and durability of TCE therapies and aim to enhance tumor selectivity, modulate the tumor microenvironment, and enable targeting of difficult-to-drug antigens.¹ Approaches include converting immunologically “cold” tumors into “hot” tumors and incorporating multi-specific binding to improve T-cell activation while limiting systemic toxicity.³

The company’s pipeline includes six programs across oncology and immunology. Its lead candidate, EXP011 (CTM012), is a tri-specific antibody targeting DLL3, CD3, and 4-1BB and is currently in a Phase I/II trial for small cell lung cancer and neuroendocrine tumors. The first patient was dosed in October 2025.

Additional candidates include EXP012, targeting CDH17-expressing gastrointestinal tumors, and programs leveraging Immune Shield and Probody technologies to address tumor microenvironment constraints and enable selective activation at disease sites.

What does the financing signal about China’s biotech innovation model?

The scale and speed of Excalipoint’s financing and pipeline development reflect the growing role of China’s biotech sector in global drug innovation, particularly through the “NewCo” model, which integrates experienced leadership, venture capital, and pipeline assets to accelerate development timelines.¹

“Excalipoint is developing a proprietary pipeline and three powerful technology platforms to position our company as a true innovation powerhouse and developer of T-cell engagers,” said Lei Fang, PhD, co-founder, chairman and CEO, Excalipoint Therapeutics, in the release.¹ “By combining science and capital with China’s clinical development efficiency and access to large patient populations, we can rapidly generate clinical data while advancing a pipeline of differentiated therapies.”

“Our progress reflects the strength and maturity of China’s biotech ecosystem, which has become an essential part of the global innovation value chain,” Dr. Fang added. “The strong support from top-tier investors validates both our science and this new approach to building a globally competitive biotechnology company.”

The company’s rapid transition from launch to clinical-stage development, including initiation of a Phase I/II trial for its lead asset, highlights increasing efficiency in early-stage biologics development. As investment continues to support platform-based immunotherapy approaches, next-generation TCE technologies may expand beyond hematologic cancers into solid tumors and immunologic diseases, where unmet need remains high.²

References

1. Excalipoint Therapeutics. Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Generation T-Cell Engager Therapies. Press Release. March 18, 2026. https://www.businesswire.com/news/home/20260318260662/en/Excalipoint-Therapeutics-Launches-with-%2468.7-Million-to-Develop-Next-Generation-T-Cell-Engager-Therapies
2. Baeuerle PA, Wesche H. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr. Opin. Oncol. 2022;34(5):552-558. doi: 10.1097/CCO.0000000000000869
3. Kang X, Zhao Y, Ling H, Huang X. Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. Antibody Ther. 2025;9(1):58-69. doi: 10.1093/abt/tbaf026